Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 10 of 21 for:    relugolix

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03204318
Recruitment Status : Active, not recruiting
First Posted : July 2, 2017
Last Update Posted : July 28, 2020
Sponsor:
Information provided by (Responsible Party):
Myovant Sciences GmbH

Tracking Information
First Submitted Date  ICMJE June 27, 2017
First Posted Date  ICMJE July 2, 2017
Last Update Posted Date July 28, 2020
Actual Study Start Date  ICMJE December 7, 2017
Actual Primary Completion Date June 9, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 24, 2020)
  • Percentage Of Participants Who Meet The Dysmenorrhea Responder Criteria At Week 24 Or End Of Treatment (EOT) [ Time Frame: Week 24 or EOT ]
    Assessed using a Numerical Rating Scale (NRS) score (11-point scale) for pain recorded daily in an electronic diary (e-Diary). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.
  • Percentage Of Participants Who Meet The Non-Menstrual Pelvic Pain (NMPP) Responder Criteria At Week 24 Or EOT [ Time Frame: Week 24 or EOT ]
    Assessed using an NRS score (11-point scale) for pain recorded daily in an e-Diary. The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.
Original Primary Outcome Measures  ICMJE
 (submitted: June 28, 2017)
  • Proportion of responders based on daily assessment of dysmenorrhea [ Time Frame: 24 weeks ]
    As recorded in a daily electronic diary
  • Proportion of responders based on daily assessment of nonmenstrual pelvic pain [ Time Frame: 24 weeks ]
    As recorded in a daily electronic diary
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 24, 2020)
  • Change From Baseline In The Endometriosis Health Profile (EHP)-30 Pain Score At Week 24 [ Time Frame: Baseline, Week 24 ]
    Assessed using the Pain Domain of the EHP-30 questionnaire.
  • Change From Baseline In Dysmenorrhea NRS Score At Week 24 Or EOT [ Time Frame: Baseline, Week 24 or EOT ]
    Assessed using an NRS score (11-point scale) for pain recorded daily in an e-Diary.
  • Change From Baseline In NMPP NRS Score At Week 24 Or EOT [ Time Frame: Baseline, Week 24 or EOT ]
    Assessed using an NRS score (11-point scale) for pain recorded daily in an e-Diary.
  • Change From Baseline In Overall Pelvic Pain NRS Score At Week 24 Or EOT [ Time Frame: Baseline, Week 24 or EOT ]
    Assessed using an NRS score (11-point scale) for pain recorded daily in an e-Diary.
  • Percentage Of Participants Who Are Not Using Opioids For Endometriosis-associated Pain At Week 24 Or EOT [ Time Frame: Week 24 or EOT ]
    Assessed based on usage of protocol-specified opioids for endometriosis-associated pain recorded daily in an e-Diary.
  • Change From Baseline In Dyspareunia NRS Scores At Week 24 Or EOT [ Time Frame: Baseline, Week 24 or EOT ]
    Assessed using an NRS score (11-point scale) for dyspareunia recorded daily in an e-Diary.
  • Change From Baseline In Analgesic Use For Endometriosis-associated Pain Based On Mean Pill Count At Week 24 Or EOT [ Time Frame: Baseline, Week 24 or EOT ]
    Assessed based on usage of protocol-specified analgesic for endometriosis-associated pain recorded daily in an e-Diary.
  • Percentage Of Participants Who Have A Reduction Of At Least 20 Points In The EHP-30 Pain Domain From Baseline To Week 24 [ Time Frame: Baseline to Week 24 ]
    Assessed using the pain domain of the EHP-30 questionnaire.
  • Dysmenorrhea Responder Rate By Month [ Time Frame: Baseline to Week 24 ]
    The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.
  • NMPP Responder Rate By Month [ Time Frame: Baseline to Week 24 ]
    The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.
  • Change In Dysmenorrhea NRS Score By Month [ Time Frame: Baseline to Week 24 ]
    Assessed using an NRS score (11-point scale) for pain recorded daily in an e-Diary.
  • Change In NMPP NRS Score By Month [ Time Frame: Baseline to Week 24 ]
    Assessed using an NRS score (11-point scale) for pain recorded daily in an e-Diary.
  • Change In Overall Pelvic Pain NRS Score By Month [ Time Frame: Baseline to Week 24 ]
    Assessed using an NRS score (11-point scale) for pain recorded daily in an e-Diary.
  • Change In Dyspareunia NRS Score By Month [ Time Frame: Baseline to Week 24 ]
    Assessed using an NRS score (11-point scale) for pain recorded daily in an e-Diary.
  • Change From Baseline In Ibuprofen Use At Week 24 Or EOT [ Time Frame: Baseline, Week 24 or EOT ]
    Assessed using ibuprofen pill counts for endometriosis-associated pain recorded daily in an e-Diary.
  • Change From Baseline In Opioid Use At Week 24 Or EOT [ Time Frame: Baseline, Week 24 or EOT ]
    Assessed using opioid pill counts for endometriosis-associated pain recorded daily in an e-Diary.
  • Change From Baseline In The Mean Dysmenorrhea Functional Impairment At Week 24 Or EOT [ Time Frame: Baseline, Week 24 or EOT ]
    Assessed using the subject modified Biberoglu and Behrman 5-point scale for dysmenorrhea recorded daily in an e-Diary.
  • Change From Baseline In The Mean NMPP Functional Impairment At Week 24 Or EOT [ Time Frame: Baseline, Week 24 or EOT ]
    Assessed using the subject modified Biberoglu and Behrman 4-point scale for pelvic pain recorded daily in an e-Diary.
  • Change From Baseline In The Mean Dyspareunia Functional Impairment At Week 24 Or EOT [ Time Frame: Baseline, Week 24 or EOT ]
    Assessed using the subject modified Biberoglu and Behrman 5-point scale for dyspareunia recorded daily in an e-Diary.
  • Change From Baseline In Patient Global Assessment (PGA) For Dysmenorrhea Symptom Severity At Week 24 [ Time Frame: Baseline, Week 24 ]
    The PGA for dysmenorrhea is a 1-item questionnaire designed to assess participants' impression of the severity of pain during their menstrual cycle.
  • Percentage Of Participants With Improvement, No Change, Or Worsening From Baseline In PGA For Dysmenorrhea At Week 24 [ Time Frame: Week 24 ]
    The PGA for dysmenorrhea is a 1-item questionnaire designed to assess participants' impression of the severity of pain during their menstrual cycle.
  • Change From Baseline In PGA For NMPP Symptom Severity At Week 24 [ Time Frame: Baseline, Week 24 ]
    The PGA for NMPP is a 1-item questionnaire designed to assess participants' impression of the severity of pain when they are not menstruating.
  • Percentage Of Participants With Improvement, No Change, Or Worsening From Baseline In PGA For NMPP At Week 24 [ Time Frame: Week 24 ]
    The PGA for NMPP is a 1-item questionnaire designed to assess participants' impression of the severity of pain when they are not menstruating.
  • Change From Baseline In PGA For Pain Severity At Week 24 [ Time Frame: Baseline, Week 24 ]
    The PGA for pain severity is a 1-item questionnaire designed to assess participants' impression of how their pain affected their usual activities.
  • Percentage Of Participants With Improvement, No Change, Or Worsening From Baseline In PGA For Pain Severity At Week 24 [ Time Frame: Week 24 ]
    The PGA for pain severity is a 1-item questionnaire designed to assess participants' impression of how their pain affected their usual activities.
  • Change From Baseline In PGA For Function At Week 24 [ Time Frame: Baseline, Week 24 ]
    The PGA for function is a 1-item questionnaire designed to assess participants' impression of how their pain affected their usual activities.
  • Percentage Of Participants With Improvement, No Change, Or Worsening From Baseline In PGA For Function At Week 24 [ Time Frame: Week 24 ]
    The PGA for function is a 1-item questionnaire designed to assess participants' impression of how their pain affected their usual activities.
  • Percentage Of Participants Who Are "Better" Or "Much Better" On The Patient Global Impression Of Change (PGIC) For Dysmenorrhea At Week 24 [ Time Frame: Week 24 ]
    The PGIC for dysmenorrhea is a 1-item questionnaire designed to assess participants' impression of change in the severity of pain during their menstrual cycle.
  • Percentage Of Participants Who Are "Better" Or "Much Better" On The PGIC For NMPP At Week 24 [ Time Frame: Week 24 ]
    The PGIC for NMPP is a 1-item questionnaire designed to assess participants' impression of change in the severity of pain during their menstrual cycle.
  • Percentage Of Participants Who Are "Better" Or "Much Better" On The PGIC For Dyspareunia At Week 24 [ Time Frame: Week 24 ]
    The PGIC for dyspareunia is a 1-item questionnaire designed to assess participants' impression of change in the severity of pain during sexual intercourse.
  • Change From Baseline In The Non-Pain Of The EHP-30 Domains At Week 24 [ Time Frame: Baseline, Week 24 ]
    Assessed using the non-pain domains (Control and Powerlessness, Social Support, Emotional Well-Being, and Self-Image) of the EHP-30 questionnaire.
  • Change From Baseline In The EHP-30 Scale Total Score At Week 24 [ Time Frame: Baseline, Week 24 ]
    Assessed using the total score of the EHP-30 questionnaire.
  • Change From Baseline In The EHP Work Domain Score At Week 24 [ Time Frame: Baseline, Week 24 ]
    The EHP Work domain is a 5-item questionnaire that assesses impact of pain on ability to work.
  • Categorical Change From Baseline In Quality Of Life Assessed By European Quality Of Life Five Dimension Five Level (EQ-5D-5L) Questionnaire At Week 24 [ Time Frame: Baseline, Week 24 ]
    The EQ-5D-5L is a 5-item questionnaire designed to assess quality of life.
  • Change From Baseline To Week 24 In EQ-5D-5L Visual Analogue Scale Score At Week 24 [ Time Frame: Baseline, Week 24 ]
    The EQ-5D-5L is a 5-item questionnaire designed to assess quality of life.
  • Percentage Of Participants Who Meet The Dysmenorrhea Responder Criteria At Week 24 Or EOT For Relugolix Plus Delayed E2/NETA [ Time Frame: Week 24 or EOT ]
    Assessed using an NRS score (11-point scale) for pain recorded daily in an e-Diary. The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.
  • Percentage Of Participants Who Meet The NMPP Responder Criteria At Week 24 Or EOT For Relugolix Plus Delayed E2/NETA [ Time Frame: Week 24 or EOT ]
    Assessed using an NRS score (11-point scale) for pain recorded daily in an e-Diary. The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.
  • Change From Baseline In The EHP-30 Pain Score At Week 24 For Relugolix Plus Delayed E2/NETA [ Time Frame: Baseline, Week 24 ]
    Assessed using the Pain Domain of the EHP-30 questionnaire.
  • Percentage Of Participants Who Have A Reduction Of At Least 20 Points In The EHP-30 Pain Domain From Baseline To Week 24 For Relugolix Plus Delayed E2/NETA [ Time Frame: Baseline to Week 24 ]
    Assessed using the pain domain of the EHP-30 questionnaire.
  • Percentage Change From Baseline In Bone Mineral Density At The Lumbar Spine (L1-L4) At Week 12 [ Time Frame: Baseline, Week 12 ]
    Assessed by dual-energy X-ray absorptiometry (DXA) scan.
  • Percentage Change From Baseline In Bone Mineral Density At Lumbar Spine (L1-L4), Femoral Neck, And Total Hip At Week 24 [ Time Frame: Baseline, Week 24 ]
    Assessed by DXA scan.
  • Percentage Of Participants Experiencing Vasomotor Symptoms At Week 12 Between Group A And B [ Time Frame: Week 12 ]
  • Change From Baseline In Serum Concentrations Of Luteinizing Hormone, Follicle Stimulating Hormone, Estradiol, And Progesterone [ Time Frame: Baseline, Week 24 ]
    Blood samples will be collected from participants for hormonal measurements.
  • Pre-dose Relugolix Plasma Concentrations [ Time Frame: Week 4 ]
    Blood samples will be collected from participants for relugolix measurements.
  • Endometrial Biopsy At Week 24 [ Time Frame: Week 24 ]
    Primary diagnosis of endometrial biopsy assessment by pathologist.
Original Secondary Outcome Measures  ICMJE
 (submitted: June 28, 2017)
Change from Baseline in the Endometriosis Health Profile (EHP)-30 Pain Domain Group [ Time Frame: 24 weeks ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain
Official Title  ICMJE SPIRIT 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain
Brief Summary The purpose of this study is to determine the benefit and safety of relugolix 40 milligrams (mg) once daily, co-administered with low-dose estradiol (E2) and norethindrone acetate (NETA) compared with placebo for 24 weeks, on dysmenorrhea and on nonmenstrual pelvic pain.
Detailed Description

This study is an international phase 3 randomized, double-blind, placebo-controlled efficacy and safety study to evaluate 24 weeks of oral, once-daily relugolix (40 mg) co-administered with either 12 or 24 weeks of low-dose E2 (1.0 mg) and NETA (0.5 mg), compared with placebo.

Approximately 600 women with endometriosis-associated pain will be enrolled and randomized 1:1:1 to Group A - relugolix plus low-dose hormonal add-back therapy, Group B - relugolix monotherapy for 12 weeks followed by co-administration with low-dose hormonal add-back therapy, or Group C - placebo (N = 200 per group).

Eligible participants were randomized on Baseline Day 1 to Treatment Group A, B, or C, in the double-blind period.

Eligible participants, including those randomized to placebo, were offered the opportunity to enroll in an 80-week open-label extension study where participants received relugolix co-administered with low-dose E2 and NETA. Participants who did not enroll into the extension study had a Follow-Up visit approximately 30 days after the participant's last dose of study drug.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Endometriosis Related Pain
Intervention  ICMJE
  • Drug: Relugolix
    Relugolix 40-mg tablet administered orally once daily.
    Other Names:
    • TAK-385
    • MVT-601
  • Drug: Estradiol/norethindrone acetate
    Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.
    Other Name: E2/NETA
  • Drug: Estradiol/norethindrone acetate placebo
    E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
  • Drug: Relugolix placebo
    Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
Study Arms  ICMJE
  • Experimental: Relugolix plus E2/NETA (Group A)
    Relugolix co-administered with E2/NETA for 24 weeks.
    Interventions:
    • Drug: Relugolix
    • Drug: Estradiol/norethindrone acetate
  • Experimental: Relugolix plus Delayed E2/NETA (Group B)
    Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
    Interventions:
    • Drug: Relugolix
    • Drug: Estradiol/norethindrone acetate
    • Drug: Estradiol/norethindrone acetate placebo
  • Placebo Comparator: Placebo (Group C)
    Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
    Interventions:
    • Drug: Estradiol/norethindrone acetate placebo
    • Drug: Relugolix placebo
Publications * Rolla E. Endometriosis: advances and controversies in classification, pathogenesis, diagnosis, and treatment. F1000Res. 2019 Apr 23;8. pii: F1000 Faculty Rev-529. doi: 10.12688/f1000research.14817.1. eCollection 2019. Review.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: July 24, 2020)
638
Original Estimated Enrollment  ICMJE
 (submitted: June 28, 2017)
600
Estimated Study Completion Date  ICMJE May 31, 2021
Actual Primary Completion Date June 9, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Key Inclusion Criteria:

  1. Is a premenopausal female aged 18 to 50 years old (inclusive) on the day of signing of the informed consent form.
  2. Has agreed to use only study-specified analgesic medications during the study and is not known to be intolerant to these.
  3. Has a diagnosis of endometriosis and has had, within 10 years prior to signing the informed consent form, surgical or direct visualization and/or histopathologic confirmation of endometriosis, for example, during a laparoscopy or laparotomy.
  4. During the Run-In Period (35 to 70 days prior to treatment period) has a dysmenorrhea NRS score ≥ 4.0 on at least 2 days and

    1. Mean NMPP NRS score ≥ 2.5, or
    2. Mean NMPP NRS score ≥ 1.25 and NMPP NRS score ≥ 5.0 on ≥ 4 days.

Key Exclusion Criteria:

  1. Has a history of chronic pelvic pain that is not caused by endometriosis.
  2. Has any chronic pain or frequently recurring pain condition, other than endometriosis that is treated with opioids or requires analgesics for ≥ 7 days per month.
  3. Has had surgical procedures for treatment of endometriosis within the 3 months prior to the Screening visit.
  4. Has a history of or currently has osteoporosis or other metabolic bone disease.
  5. Has a clinically significant gynecologic condition, other than endometriosis, identified during Screening or Run-In period transvaginal ultrasound or endometrial biopsy.
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 18 Years to 50 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Belgium,   Bulgaria,   Canada,   Czechia,   Finland,   Hungary,   Poland,   Portugal,   South Africa,   Spain,   Ukraine,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03204318
Other Study ID Numbers  ICMJE MVT-601-3101
2017-001588-19 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Myovant Sciences GmbH
Study Sponsor  ICMJE Myovant Sciences GmbH
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Myovant Medical Monitor Myovant Sciences
PRS Account Myovant Sciences GmbH
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP